UNSPSC 51124103: Adenosine phosphate

This classification denotes an aprt gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 415SHH325A. European Medicines Agency schedules Adenosine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05267MIG. Adenosine phosphate generally arises in the molecular formula C10H14N5O7P. The term ADENOSINE PHOSPHATE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule adenosine phosphate under HS 29349990 and SITC 51579.

As of Q4 2014, ADENOSINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Adenosine phosphate bears US NLM identifiers UMLS ID C0001413 and NCI Concept Code C83606. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N.

UNSPSC 51124103 Adenosine phosphate is a Commodity code that covers pharmaceutical active ingredients and finished-form emergency medications for state and local use, specifically adenosine and related cardiac resuscitation agents. State and local governments procure these drugs through direct purchases for emergency medical services, public health programs, and cooperative purchasing arrangements with wholesalers and manufacturers. The recent solicitations show demand concentrated in fire rescue services and statewide pharmacy benefit programs. Issuing bodies include municipal fire departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and government agencies.

Activity appears in three distinct forms: direct municipal procurement (City of Tampa's purchase of 330 units of adenosine 6mg vials for Tampa Fire Rescue via sealed bid), statewide pharmacy benefit market research (Texas Health and Human Services Commission's exploratory RFI into direct-to-manufacturer prescription programs), and multistate cooperative agreements (Minnesota Multistate Cooperative Purchasing Alliance RFP for generic pharmaceuticals including adenosine through authorized wholesalers). The Tampa bid closed April 8, 2026, with an estimated contract value of $40,000 and a one-year term; the Minnesota MMCAP RFP, due March 26, 2026, covers a two-year term across multiple states including Oregon. Geographic concentration spans Texas, Minnesota, Florida, and participating MMCAP jurisdictions. Vendors supplying under this code must meet FDA requirements, maintain minimum shelf life (six months to nine months from delivery), obtain cGMP and Drug Supply Chain Security Act certification, establish relationships with authorized wholesalers, and comply with OSHA Hazard Communication Standards for safety documentation.